-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] In recent years, under the influence of a series of new medical reform policies such as domestic medical insurance and centralized procurement, a large number of domestic and foreign pharmaceutical companies have had to adjust their business, and at the same time abolish or adjust related sales teams
.
Recently, a number of media reports said that the Italian pharmaceutical company Dongpei Pharmaceuticals has stopped promoting its Senaijimin eye drops (Ouxiwei) in China, and the company has basically disbanded its sales team
.
In addition to disbanding the sales team, it is reported that the "Wei You Lighting" patient welfare project jointly launched by Dongpei Pharmaceuticals and Magnesium Health will also officially end at the end of March 2022
.
So why did the company disband the sales team? It is understood that Dongpei Pharma’s Senajimin eye drops (Ouxiwei) was officially approved to enter the Chinese commercial market in August 2020.
The indication is for the treatment of moderate or severe neurotrophic keratitis (NK).
.
NK is a rare disease.
It is a corneal degenerative disease caused by trigeminal nerve injury, which can lead to decreased or absent corneal sensation, reduced nutrient supply to corneal cells, and affects the production of tear film, the number of blinks, and the healing process of the cornea
.
According to the first "Investigation Report on Disease Burden of Neurotrophic Keratitis Patients in China" released by China Rare Disease Alliance and Ai Kunwei, about 50% of patients are already moderately severe at the time of diagnosis
.
This group of patients has an urgent need for related treatments
.
As early as April 2020, Dongpei Pharmaceutical signed a strategic cooperation agreement with the China Rare Disease Alliance
.
At that time, the two parties will start from a single disease of neurotrophic keratitis, and cooperate to explore various aspects of business such as clinical diagnosis and treatment of rare ophthalmic diseases in China, disease management, and medication guarantee
.
In August of the same year, after Oxvi was launched in China, it brought new treatment options to patients
.
However, rare disease treatment drugs are generally expensive, and the same is true for Oxvi
.
According to public channels, the reference price of the drug is about 36,000 yuan per box (10 sticks), a course of treatment is 8 weeks, and the total cost of therapy is about 140,000 yuan, which is a big deal for most domestic patient families.
small expenses
.
In recent years, in order to reduce the burden of rare disease patients, the National Medical Insurance Bureau has continuously issued policies to include some rare disease drugs into the scope of medical insurance and centralized procurement
.
However, in the two rounds of medical insurance catalog adjustment in 2020 and 2021, Ou Shiwei failed to be successfully shortlisted
.
The industry pointed out that although Dongpei Pharmaceutical has also launched the "Weiyou Lighting" patient welfare project with Meixin Health in early 2021 to reduce the pressure on patients to pay, but the project will cost about 60,000 yuan for the entire course of treatment, which is still not a sum of money.
A small fee, which also has a big impact on the accessibility of Oxvi
.
Analysts believe that the decision to suspend the promotion of products and abolish the sales team may be due to the difficulty of Oxvi's popularity in the Chinese market
.
It has been less than 2 years since the product entered the Chinese market
.
However, although the sales team was basically withdrawn, Dongpei Pharmaceutical still retained a small number of medical department personnel in the Chinese market
.
It is reported that if the hospital needs to use Ouxiwei, it will be provided by Dongpei Pharmaceutical for one-time delivery
.
According to the data, the main strategic markets of Dongpei Pharmaceutical include Italy, the United States, and China.
The company's main focus areas are ophthalmology, transplantation, oncology and metabolism
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Recently, a number of media reports said that the Italian pharmaceutical company Dongpei Pharmaceuticals has stopped promoting its Senaijimin eye drops (Ouxiwei) in China, and the company has basically disbanded its sales team
.
In addition to disbanding the sales team, it is reported that the "Wei You Lighting" patient welfare project jointly launched by Dongpei Pharmaceuticals and Magnesium Health will also officially end at the end of March 2022
.
So why did the company disband the sales team? It is understood that Dongpei Pharma’s Senajimin eye drops (Ouxiwei) was officially approved to enter the Chinese commercial market in August 2020.
The indication is for the treatment of moderate or severe neurotrophic keratitis (NK).
.
NK is a rare disease.
It is a corneal degenerative disease caused by trigeminal nerve injury, which can lead to decreased or absent corneal sensation, reduced nutrient supply to corneal cells, and affects the production of tear film, the number of blinks, and the healing process of the cornea
.
According to the first "Investigation Report on Disease Burden of Neurotrophic Keratitis Patients in China" released by China Rare Disease Alliance and Ai Kunwei, about 50% of patients are already moderately severe at the time of diagnosis
.
This group of patients has an urgent need for related treatments
.
As early as April 2020, Dongpei Pharmaceutical signed a strategic cooperation agreement with the China Rare Disease Alliance
.
At that time, the two parties will start from a single disease of neurotrophic keratitis, and cooperate to explore various aspects of business such as clinical diagnosis and treatment of rare ophthalmic diseases in China, disease management, and medication guarantee
.
In August of the same year, after Oxvi was launched in China, it brought new treatment options to patients
.
However, rare disease treatment drugs are generally expensive, and the same is true for Oxvi
.
According to public channels, the reference price of the drug is about 36,000 yuan per box (10 sticks), a course of treatment is 8 weeks, and the total cost of therapy is about 140,000 yuan, which is a big deal for most domestic patient families.
small expenses
.
In recent years, in order to reduce the burden of rare disease patients, the National Medical Insurance Bureau has continuously issued policies to include some rare disease drugs into the scope of medical insurance and centralized procurement
.
However, in the two rounds of medical insurance catalog adjustment in 2020 and 2021, Ou Shiwei failed to be successfully shortlisted
.
The industry pointed out that although Dongpei Pharmaceutical has also launched the "Weiyou Lighting" patient welfare project with Meixin Health in early 2021 to reduce the pressure on patients to pay, but the project will cost about 60,000 yuan for the entire course of treatment, which is still not a sum of money.
A small fee, which also has a big impact on the accessibility of Oxvi
.
Analysts believe that the decision to suspend the promotion of products and abolish the sales team may be due to the difficulty of Oxvi's popularity in the Chinese market
.
It has been less than 2 years since the product entered the Chinese market
.
However, although the sales team was basically withdrawn, Dongpei Pharmaceutical still retained a small number of medical department personnel in the Chinese market
.
It is reported that if the hospital needs to use Ouxiwei, it will be provided by Dongpei Pharmaceutical for one-time delivery
.
According to the data, the main strategic markets of Dongpei Pharmaceutical include Italy, the United States, and China.
The company's main focus areas are ophthalmology, transplantation, oncology and metabolism
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
